| pubmed-article:7917909 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7917909 | lifeskim:mentions | umls-concept:C0027651 | lld:lifeskim |
| pubmed-article:7917909 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:7917909 | lifeskim:mentions | umls-concept:C0025202 | lld:lifeskim |
| pubmed-article:7917909 | lifeskim:mentions | umls-concept:C0443315 | lld:lifeskim |
| pubmed-article:7917909 | lifeskim:mentions | umls-concept:C0033262 | lld:lifeskim |
| pubmed-article:7917909 | lifeskim:mentions | umls-concept:C0013089 | lld:lifeskim |
| pubmed-article:7917909 | lifeskim:mentions | umls-concept:C0242732 | lld:lifeskim |
| pubmed-article:7917909 | lifeskim:mentions | umls-concept:C0591833 | lld:lifeskim |
| pubmed-article:7917909 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:7917909 | pubmed:dateCreated | 1994-11-8 | lld:pubmed |
| pubmed-article:7917909 | pubmed:abstractText | Doxorubicin (5 mg kg-1) was administered intravenously to C57 mice bearing subcutaneous B16F10 melanomas, distributing into the tumour with an area under the concentration-time curve (0-48 h; AUC) of 8.7 micrograms h g-1. Injection of doxorubicin-N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugate, containing 5 mg of doxorubicin equivalent per kg, mediated an AUC for free doxorubicin (i.e. doxorubicin released from the conjugate) of 15.2 micrograms h g-1 and for total doxorubicin (i.e. free plus conjugated) of 149.1 micrograms h g-1. An increased dose of doxorubicin-HPMA copolymer conjugate (18 mg of doxorubicin equivalent per kg) produced AUC values of 40.1 micrograms h g-1 and 671.7 micrograms h g-1 for free and total doxorubicin respectively. Hence administration of doxorubicin-HPMA copolymer conjugate achieved rises of 1.7- to 4.6-fold in tumour AUC (free doxorubicin) and 17.19 to 77.0-fold in tumour AUC (total doxorubicin). HPMA copolymers bearing fluorescein isothiocyanate accumulated in vascularised stromal regions, particularly in new growth sites at the tumour periphery. Treatment of mice with doxorubicin-HPMA copolymer conjugate achieved treated/control lifespans up to 320% (three doses of 27 mg of doxorubicin equivalent per kg) compared with only 133% using aggressive regimens of free doxorubicin (3 x 5 mg kg-1). | lld:pubmed |
| pubmed-article:7917909 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7917909 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7917909 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7917909 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7917909 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7917909 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7917909 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7917909 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7917909 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7917909 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7917909 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7917909 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7917909 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7917909 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7917909 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7917909 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7917909 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7917909 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7917909 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7917909 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7917909 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7917909 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7917909 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7917909 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7917909 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7917909 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:7917909 | pubmed:issn | 0007-0920 | lld:pubmed |
| pubmed-article:7917909 | pubmed:author | pubmed-author:DuncanRR | lld:pubmed |
| pubmed-article:7917909 | pubmed:author | pubmed-author:UlbrichKK | lld:pubmed |
| pubmed-article:7917909 | pubmed:author | pubmed-author:SubaEE | lld:pubmed |
| pubmed-article:7917909 | pubmed:author | pubmed-author:SeymourL WLW | lld:pubmed |
| pubmed-article:7917909 | pubmed:author | pubmed-author:StrohalmJJ | lld:pubmed |
| pubmed-article:7917909 | pubmed:author | pubmed-author:SteygerP SPS | lld:pubmed |
| pubmed-article:7917909 | pubmed:author | pubmed-author:BreretonMM | lld:pubmed |
| pubmed-article:7917909 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7917909 | pubmed:volume | 70 | lld:pubmed |
| pubmed-article:7917909 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7917909 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7917909 | pubmed:pagination | 636-41 | lld:pubmed |
| pubmed-article:7917909 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:7917909 | pubmed:meshHeading | pubmed-meshheading:7917909-... | lld:pubmed |
| pubmed-article:7917909 | pubmed:meshHeading | pubmed-meshheading:7917909-... | lld:pubmed |
| pubmed-article:7917909 | pubmed:meshHeading | pubmed-meshheading:7917909-... | lld:pubmed |
| pubmed-article:7917909 | pubmed:meshHeading | pubmed-meshheading:7917909-... | lld:pubmed |
| pubmed-article:7917909 | pubmed:meshHeading | pubmed-meshheading:7917909-... | lld:pubmed |
| pubmed-article:7917909 | pubmed:meshHeading | pubmed-meshheading:7917909-... | lld:pubmed |
| pubmed-article:7917909 | pubmed:meshHeading | pubmed-meshheading:7917909-... | lld:pubmed |
| pubmed-article:7917909 | pubmed:meshHeading | pubmed-meshheading:7917909-... | lld:pubmed |
| pubmed-article:7917909 | pubmed:meshHeading | pubmed-meshheading:7917909-... | lld:pubmed |
| pubmed-article:7917909 | pubmed:meshHeading | pubmed-meshheading:7917909-... | lld:pubmed |
| pubmed-article:7917909 | pubmed:meshHeading | pubmed-meshheading:7917909-... | lld:pubmed |
| pubmed-article:7917909 | pubmed:meshHeading | pubmed-meshheading:7917909-... | lld:pubmed |
| pubmed-article:7917909 | pubmed:meshHeading | pubmed-meshheading:7917909-... | lld:pubmed |
| pubmed-article:7917909 | pubmed:meshHeading | pubmed-meshheading:7917909-... | lld:pubmed |
| pubmed-article:7917909 | pubmed:meshHeading | pubmed-meshheading:7917909-... | lld:pubmed |
| pubmed-article:7917909 | pubmed:year | 1994 | lld:pubmed |
| pubmed-article:7917909 | pubmed:articleTitle | Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma. | lld:pubmed |
| pubmed-article:7917909 | pubmed:affiliation | Institute for Cancer Studies, University of Birmingham School of Medicine, UK. | lld:pubmed |
| pubmed-article:7917909 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7917909 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7917909 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7917909 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7917909 | lld:pubmed |
